JAMA Network Home
Sign In
Viewpoint

Telemedicine Special Registrations for Controlled Substances

JAMA Health Forum 10.1001/jamahealthforum.2025.2795

July 25, 2025 at 11:00 AM EDT

Read the full article

This Viewpoint discusses the Drug Enforcement Agency’s aim to limit diversion of controlled substances with special registration requirements for telemedicine visits.

Corresponding Author: Jacob T. Kannarkat, MD, Department of Psychiatry, Yale School of Medicine, 300 George St, New Haven, CT 06511 (jacob.kannarkat@yale.edu).

Link to the article in your story

We encourage you to link out to this article in your your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.2795?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=072525

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks